Results 231 to 240 of about 190,120 (268)

Lung organoids as a human system for Mycobacteria infection modeling and drug testing

The FEBS Journal, EarlyView.
Mycobacterial infections, including tuberculosis (TB) and infections by nontuberculous mycobacteria (NTM), are still public health issues. In 2023, TB caused 1.25 million deaths, while NTM remain a clinical challenge for patients with cystic fibrosis (CF).
Stephen Adonai Leon‐Icaza, Romain Vergé, Raoul Mazars, Laurence Berry, Céline Cougoule   +4 more
wiley   +1 more source

Utility of the Caprini risk assessment model in guiding venous thromboembolism prophylaxis after abdominoplasty. [PDF]

JPRAS Open
Asiry A, Sayegh A, Gangloff D, Mortada H, Gandolfi S, Lupon E.   +5 more
europepmc   +1 more source

Policy Adherence to Antithrombotic Therapy for Prophylactic Anticoagulation in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19. [PDF]

J Pediatr Clin Pract
Clouser AA, Procaccini D, Lawrence CE, Sick-Samuels AC, Lee CKK.   +4 more
europepmc   +1 more source

Inter-Observer Agreement and Laboratory Correlation of the 4T Scoring Model for Heparin-Induced Thrombocytopenia: A Single-Center Retrospective Study and Literature Review. [PDF]

J Clin Med
Aljumaa RM, Dabaliz A, Sabur H, Mushtaq A, Aljumaa MM, Tamim H, Owaidah T, Sajid MR.   +7 more
europepmc   +1 more source

Effect of sodium citrate anticoagulant solution in continuous veno-venous hemofiltration in critically ill children. [PDF]

BMC Pediatr
Ye X, Zhang S, Tang M.
europepmc   +1 more source

Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a systematic review of efficacy, safety, and cost-effectiveness. [PDF]

Front Pharmacol
Li B, Zhao L.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Low molecular weight heparins

Expert Opinion on Pharmacotherapy, 2000
Since its discovery, nearly 90 years, heparin has been used successfully for the treatment of thromboembolic processes. However, therapy with heparin has several important limitations. Most importantly, the poor predictability of its anticoagulant effects has led to the development of the low molecular weight heparins (LMWHs), which are derived from ...
O M, Aguilar, N S, Kleiman
openaire   +3 more sources

Low molecular weight heparins

Current Opinion in Cardiology, 1994
Low molecular weight heparins are derived from unfractionated heparin by chemical or enzymatic depolymerization; as a result, the mean molecular weight of unfractionated heparin is reduced by about one third and its biochemical and pharmacologic properties are improved.
B, Cosmi, J, Hirsh
openaire   +2 more sources